Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-342-7 | CAS number: 1163775-81-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19-May-2016 to 09-Sept-2016
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
- Objective of study:
- bioaccessibility (or bioavailability)
- toxicokinetics
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Version / remarks:
- Version adopted 22-July-2010
- Deviations:
- yes
- Remarks:
- For toxicokinetic arm of study, only two animals of each gender were studied rather than the four stipulated in the test guidelines.
- Principles of method if other than guideline:
- N/A
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Linplast 812 TM
- IUPAC Name:
- Linplast 812 TM
- Test material form:
- liquid
- Remarks:
- Colorless
- Details on test material:
- Storage conditions: Room temperature, avoid light, dry.
Expiration date: Jan., 2017.
Constituent 1
- Specific details on test material used for the study:
- N/A
- Radiolabelling:
- no
- Remarks:
- An analytical method was developed to measure the unlabelled test material.
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- SPF Grade.
- Details on species / strain selection:
- The rat was selected for this study because it is recognized as a species commonly used in toxicology studies. The rat is recommended by the Ministry of Environmental Protection of P. R. China "The Guidelines for the Testing of Chemicals - Health Effects (2nd edition)".
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Beijing WeiTongLiHua Test Animal Technology Co. Ltd
- Age: 6-8 weeks.
- Weight at end of quarantine period: Males 301.9 to 378.9 g. Females 232.3 to 275.6 g.
- Housing: Animals were housed in groups in transparent polycarbonate boxes and each cage rack contained 3-5 animals. Study number, test substance number, animal code, group, sex, and dose were labelled on the cage cards. Cages and bedding were replaced twice a week.
- Diet: Ad libitum. Standard extruded food for test animals (source: Beijing KeaoXieli Food Co. Ltd).
- Water: Ad libitum. Municipal water. Drinking water quality was monitored.
- Quarantine: All animals were quarantined for seven (7) days. During this period, no abnormalities of animals were observed. Clinical Verterinarian checked the animals and issued quarantine inspection report before the animals were used on-study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 25
- Humidity (%): 40 - 70
- Photoperiod: 12 hrs dark /12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- The appropriate amount of the test sample plus corn oil volume, mix, dubbed with 1000 mg/mL suspension for animal exposure. The volume of administration was 10 mL/kg. Animals were fasted for at least 12 h prior to administration.
- Duration and frequency of treatment / exposure:
- A single dose of test substance was administered.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 mg/kg bw/day
- Remarks:
- iv adminstration
- Dose / conc.:
- 5 mg/kg bw/day
- Remarks:
- iv administration
- Dose / conc.:
- 10 mg/kg bw/day
- Remarks:
- iv administration
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- Remarks:
- Toxicokinetics arm of study.
- Dose / conc.:
- 50 mg/kg bw (total dose)
- Remarks:
- Digestive residue arm of study.
- No. of animals per sex per dose / concentration:
- 3 males for iv administration
2 males and 2 females for toxicokinetics arm of study.
8 males and 8 females for digestive residue arm of study. - Control animals:
- no
- Positive control reference chemical:
- N/A
- Details on study design:
- DOSE SELECTION
The dose selection was based on three preliminary experiments, details of which are provided in the pertinent RESULTS AND DISCUSSION section below.
ANALYTICAL METHOD
A LC-MS/MS method for LINPLAST 812 TM (m/z 547.4→305) was established as part of the study.
The method was validated for use in rat plasma anticoagulated by heparin in the range 50-500 ng/mL LINPLAST 812 TM.
The method was validated for use with digestive tract homogenate in the range 50-500 ng/mL LINPLAST 812 TM. - Details on dosing and sampling:
- TOXICOKINETIC ARM OF STUDY
Dosing details have already been provided.
Following dosing, approximately 0.2 mL of blood was collected via the orbital vein and was added with anticoagulant heparin solution. Blood samples were collected at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h following the dose administration and before dose administration.
Blood samples should be pretreatment and analysed as soon as possible.
DIGESTIVE RESIDUE ARM OF STUDY
Dosing details have already been provided.
After the exposure of animals placed in metabolic cages for 30 min, 2 h, 6 h, and 24 h, each time two male and two female animals were euthanized, whichever digestive tract and faeces collected after administration, the digestive tract and feces combined weighed, then immediately added 0.01 M PBS at a weight ratio of 1:5 homogenate, homogenate vortex mix, 50 μL was added to 500 μL acetonitrile and then measured. - Statistics:
- TOXICOKINETIC ARM OF STUDY
DAS2.0 pharmacokinetic program was used to analyse data and calculate the main pharmacokinetic parameters: AUC, Cmax, F, Tmax, MRT, t1/2 and so on.
DIGESTIVE RESIDUE ARM OF STUDY
Microsoft Excel was used for data processing, computing the gastrointestinal remaining amount.
Results and discussion
- Preliminary studies:
- PRELIMINARY EXPERIMENT 1
Two SD male rats were administered LINPLAST 812 TM at 20 or 1000 mg/kg by oral gavage, one male rat was administered LINPLAST 812 TM at 5 mg/kg by intravenous (iv) injection, obtained plasma to determine (plasma sample treatment: samples treated at 13000rpm, at 4 °C Centrifugal for 10min). Preliminary test results are shown in Table 1. The results indicate that LINPLAST 812 TM eliminates slowly in iv injection treatment group and can’t absorb in oral gavage group.
PRELIMINARY EXPERIMENT 2
Two SD male rats were administered LINPLAST 812 TM at 20 or 1000 mg/kg by oral gavage, one male rat was administered LINPLAST 812 TM at 5 mg/kg by intravenous (iv) injection, obtained blood to determine (sample treatment: 50 μL of rat whole blood was added into 500 μL acetonitrile). Preliminary test results are shown in Table 2. The result indicates that LINPLAST 812 TM eliminates slowly in iv injection treat group; and can’t absorb in oral gavage, without different plasma result.
PRELIMINARY EXPERIMENT 3
Two SD male rats were administered LINPLAST 812 TM at 1 or 10 mg/kg by intravenous (iv) injection, obtained plasma to determine (sample treatment: samples treated at 13000rpm, at 4 °C Centrifugal for 10min). Preliminary test results are shown in Table 3. The result indicates that LINPLAST 812 TM eliminates slowly in all iv injection treat group, and exposure level did not increase with the increase of dose.
Main ADME resultsopen allclose all
- Type:
- other: Bioavailability
- Results:
- After oral gavage, LINPLAST 812 TM prototype was undetectable in the plasma of SD rats.
- Type:
- other: Digestive residue
- Results:
- Less than 1% of the administered LINPLAST 812 TM was recovered in digestive tract and feces.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- N/A
- Details on distribution in tissues:
- N/A
- Details on excretion:
- N/A
Metabolite characterisation studies
- Metabolites identified:
- not measured
- Details on metabolites:
- N/A
Enzymatic activity
- Enzymatic activity measured:
- N/A
Bioaccessibility (or Bioavailability)
- Bioaccessibility (or Bioavailability) testing results:
- TOXICOKINETIC ARM OF STUDY
Four SD rats were administered LINPLAST 812 TM at 1000 mg/kg by oral gavage. The concentration time-course data for LINPLAST 812 TM in plasma is shown in Table 4. LINPLAST 812 TM prototype was undetectable in plasma.
DIGESTIVE RESIDUE ARM OF STUDY
Sixteen (16) rats were administered LINPLAST 812 TM at 50 mg/kg by oral gavage. The concentration time course data for LINPLAST 812 TM in plasma, digestive track, feces are shown in Table 5 to Table 7. The recovery rate time course data for LINPLAST 812 TM in plasma, digestive tract, feces are shown in Table 8 and Table 9.
At different times after oral gavage, the recovery rate of LINPLAST 812 TM in digestive tract and feces is very low, less than 1%, and LINPLAST 812 TM prototype was undetectable in plasma.
Any other information on results incl. tables
Table 1 Plasma concentration of LINPLAST 812 TM following administration in SD rats
J01 means intravenous administration, R01 and R02 means oral gavage administration, NA means not detected, BLLOQ below the low limit of quantization.
Time (h) |
Concentration of LINPLAST 812 TM in plasma (ng/mL) |
||
J01 (5 mg/kg, iv) |
R01 (20 mg/kg, ig) |
R02 (1000 mg/kg, ig) |
|
0.0166667 |
199.73 |
N/A |
N/A |
0.0833333 |
189.88 |
BLLOQ |
BLLOQ |
0.25 |
165.83 |
BLLOQ |
BLLOQ |
0.5 |
165.00 |
BLLOQ |
BLLOQ |
1 |
151.14 |
BLLOQ |
BLLOQ |
2 |
138.23 |
BLLOQ |
BLLOQ |
4 |
119.85 |
BLLOQ |
BLLOQ |
6 |
111.89 |
BLLOQ |
BLLOQ |
8 |
BLLOQ |
BLLOQ |
BLLOQ |
12 |
BLLOQ |
BLLOQ |
BLLOQ |
24 |
BLLOQ |
BLLOQ |
BLLOQ |
Table 2 The whole blood concentration of LINPLAST 812 TM following administration in SD rats
J01 means intravenous administration, R01 and R02 means oral gavage administration, NA means not detected, BLLOQ below the low limit of quantization.
Time (h) |
Concentration of LINPLAST 812 TM in whole blood (ng/mL) |
||
J01 (5 mg/kg, iv) |
R01 (20 mg/kg, ig) |
R02 (1000 mg/kg, ig) |
|
0.0166667 |
126.31 |
N/A |
N/A |
0.0833333 |
108.99 |
BLLOQ |
BLLOQ |
0.25 |
106.89 |
BLLOQ |
BLLOQ |
0.5 |
BLLOQ |
BLLOQ |
BLLOQ |
1 |
101.81 |
BLLOQ |
BLLOQ |
2 |
100.01 |
BLLOQ |
BLLOQ |
4 |
101.60 |
BLLOQ |
BLLOQ |
6 |
BLLOQ |
BLLOQ |
BLLOQ |
8 |
BLLOQ |
BLLOQ |
BLLOQ |
12 |
BLLOQ |
BLLOQ |
BLLOQ |
24 |
BLLOQ |
BLLOQ |
BLLOQ |
Table 3 Plasma concentration of LINPLAST 812 TM following administration in SD rats
J03, J04 means intravenous administration, BLLOQ below low limit of quantization.
Time (h) |
Concentration of LINPLAST 812 TM in plasma (ng/mL) |
|
J03 (1 mg/kg, iv) |
J04 (10 mg/kg, iv) |
|
0.0166667 |
79.25 |
394.48 |
0.0833333 |
84.43 |
376.48 |
0.25 |
80.44 |
351.89 |
0.5 |
78.57 |
348.58 |
1 |
72.30 |
299.75 |
2 |
74.07 |
243.01 |
4 |
59.91 |
255.68 |
6 |
57.16 |
178.23 |
8 |
52.22 |
168.81 |
12 |
BLLOQ |
130.88 |
24 |
BLLOQ |
89.17 |
Table 4 Concentration time-course data for 1000 mg/kg LINPLAST 812 TM in plasma
BLLOQ means below the low limit of quantitation (50 ng/mL).
Sampling time |
Concentration of LINPLAST 812 TM in plasma (ng/mL) |
|||
FEMALE |
MALE |
|||
R01 |
R02 |
R03 |
R04 |
|
Predose |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
15 min |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
30 min |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
1 h |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
2 h |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
4 h |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
8 h |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
24 h |
BLLOQ |
BLLOQ |
BLLOQ |
BLLOQ |
Table 5 Testing result for 50 mg/kg LINPLAST 812 TM in plasma
BLLOQ means below the low limit of quantitation (50 ng/mL).
Time (h) |
Animal No. |
Gender |
LINPLAST 812 TM (ng/mL) |
0.5 |
D01 |
F |
BLLOQ |
0.5 |
D02 |
F |
BLLOQ |
0.5 |
D03 |
M |
BLLOQ |
0.5 |
D04 |
M |
BLLOQ |
2 |
D05 |
F |
BLLOQ |
2 |
D06 |
F |
BLLOQ |
2 |
D07 |
M |
BLLOQ |
2 |
D08 |
M |
BLLOQ |
6 |
D09 |
F |
BLLOQ |
6 |
D10 |
F |
BLLOQ |
6 |
D11 |
M |
BLLOQ |
6 |
D12 |
M |
BLLOQ |
24 |
D13 |
F |
BLLOQ |
24 |
D14 |
F |
BLLOQ |
24 |
D15 |
M |
BLLOQ |
24 |
D16 |
M |
BLLOQ |
Table 6 Testing result for 50 mg/kg LINPLAST 812 TM in digestive tract homogenate
BLLOQ means below the low limit of quantitation (50 ng/mL).
Time (h) |
Animal No. |
Gender |
LINPLAST 812 TM (ng/mL) |
LINPLAST 812 TM (ng/g) |
0.5 |
D01 |
F |
111.48 |
668.88 |
0.5 |
D02 |
F |
110.24 |
661.44 |
0.5 |
D03 |
M |
91.57 |
549.42 |
0.5 |
D04 |
M |
146.65 |
879.9 |
2 |
D05 |
F |
92.03 |
552.18 |
2 |
D06 |
F |
112.92 |
677.52 |
2 |
D07 |
M |
118.26 |
709.56 |
2 |
D08 |
M |
123.20 |
739.20 |
6 |
D09 |
F |
79.08 |
474.48 |
6 |
D10 |
F |
77.81 |
466.86 |
6 |
D11 |
M |
134.61 |
807.66 |
6 |
D12 |
M |
109.67 |
658.02 |
24 |
D13 |
F |
BLLOQ |
BLLOQ |
24 |
D14 |
F |
BLLOQ |
BLLOQ |
24 |
D15 |
M |
BLLOQ |
BLLOQ |
24 |
D16 |
M |
BLLOQ |
BLLOQ |
Table 7 Testing result for 50 mg/kg LINPLAST 812 TM in feces
BLLOQ means below the low limit of quantitation (50 ng/mL).
Time (h) |
Animal No. |
Gender |
LINPLAST 812 TM (ng/mL) |
LINPLAST 812 TM (ng/g) |
0~6 |
D10 |
F |
BLLOQ |
BLLOQ |
0~6 |
D12 |
M |
BLLOQ |
BLLOQ |
6~24 |
D13 |
F |
118.86 |
713.16 |
6~24 |
D14 |
F |
212.64 |
1275.84 |
6~24 |
D15 |
M |
189.42 |
1136.52 |
6~24 |
D16 |
M |
303.93 |
1823.58 |
Table 8 Residue and recovery for 50 mg/kg LINPLAST 812 TM in digestive tract
BLLOQ means below the low limit of quantitation (50 ng/mL).
Time (h) |
Animal No. |
Exposure Amount (mg) |
Digestive Tract Weight (g) |
Digestive Tract Residues (mg) |
Recovery rate (%) |
Average Recovery (%) |
0.5 |
D01 |
13.0 |
25.580 |
0.0171 |
0.132 |
0.128 |
0.5 |
D02 |
13.0 |
28.263 |
0.0187 |
0.144 |
|
0.5 |
D03 |
18.5 |
33.301 |
0.0183 |
0.099 |
|
0.5 |
D04 |
18.0 |
28.244 |
0.0249 |
0.138 |
|
2 |
D05 |
14.5 |
36.977 |
0.0204 |
0.141 |
0.141 |
2 |
D06 |
12.5 |
25.145 |
0.0170 |
0.136 |
|
2 |
D07 |
19.5 |
39.462 |
0.0280 |
0.144 |
|
2 |
D08 |
17.5 |
33.953 |
0.0251 |
0.143 |
|
6 |
D09 |
13.0 |
28.265 |
0.0134 |
0.103 |
0.103 |
6 |
D10 |
12.5 |
19.742 |
0.0092 |
0.074 |
|
6 |
D11 |
18.0 |
29.170 |
0.0236 |
0.131 |
|
6 |
D12 |
16.5 |
26.404 |
0.0174 |
0.105 |
|
24 |
D13 |
13.5 |
17.835 |
BLLOQ |
0 |
0 |
24 |
D14 |
14.0 |
19.586 |
BLLOQ |
0 |
|
24 |
D15 |
17.0 |
18.739 |
BLLOQ |
0 |
|
24 |
D16 |
20.0 |
23.098 |
BLLOQ |
0 |
Table 9 Residue and recovery for 50 mg/kg LINPLAST 812 TM in feces
BLLOQ means below the low limit of quantitation (50 ng/mL).
Time (h) |
Animal No. |
Exposure Amount (mg) |
Feces Weight (g) |
Feces Excretion (mg) |
Recovery rate (%) |
Average Recovery (%) |
0~6 |
D10 |
12.5 |
0.932 |
BLLOQ |
0 |
0 |
0~6 |
D12 |
16.5 |
1.808 |
BLLOQ |
0 |
|
6~24 |
D13 |
13.5 |
3.001 |
0.0021 |
0.016 |
0.019 |
6~24 |
D14 |
14 |
2.927 |
0.0037 |
0.027 |
|
6~24 |
D15 |
17 |
0.998 |
0.0011 |
0.007 |
|
6~24 |
D16 |
20 |
2.721 |
0.0050 |
0.025 |
Applicant's summary and conclusion
- Conclusions:
- The absorption kinetics characteristics of LINPLAST 812 TM in rats by oral gavage is:
LINPLAST 812 TM prototype wasn’t found in plasma following gavage administration, it may be metabolized and decomposed in digestive tract and/or there has first pass effect in liver. - Executive summary:
An LC-MS/MS analytical method for LINPLAST 812 TM in rat biological samples was established. The method was based on quantifying the mass transition m/z 547.4→305. The identity of the precursor and fragment ions are not provided in the report and it is not clear whether the method measures one, more, or all of the constituents in the test material.
The method was validated for use with rat plasma. Specificity was confirmed and linearity was established over a range of 50-500 ng/mL, with the lower bound representing the LLOQ for the method. Inter- and intra-assay precision and accuracy were satisfactory. Recovery was approximately 75%. Sample and extracted sample stability was determined.
Linear range, precision, accuracy, recovery rate and matrix effects were also confirmed partially for the alimentary canal of rats.
Preliminary test results showed that LINPLAST 812 TM has slow elimination in rats administered the substance by intravenous injection. Moreover, plasma exposure did not proportionally increase with increasing dose.
After oral administration of LINPLAST 812 TM by oral gavage (1000 mg/kg), LINPLAST 812 TM prototype was undetectable in plasma. Moreover, after oral gavage administration of 50 mg/kg LINPLAST 812 TM, the recovery rate in the digestive tract and feces was less than 1%. LINPLAST 812 TM may be metabolized and decomposed in the digestive tract and/or subject to significant first-pass hepatic metabolism.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.